Cargando…

P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial

Detalles Bibliográficos
Autores principales:	Shao, Y, Li, T, Wolf, H, Liu, Y, Wang, H, Zhu, H, Lv, W, Lin, W, Chen, J, Liang, H, Hong, K, Jia, M
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767920/ http://dx.doi.org/10.1186/1742-4690-6-S3-P404

Ejemplares similares

Replication-inducible vaccinia virus vectors with enhanced safety in vivo
por: O’Connell, Caitlin M., et al.
Publicado: (2020)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
por: Goepfert, P, et al.
Publicado: (2012)

Development of replication-competent adenovirus based vaccine vectors
por: Abbink, P, et al.
Publicado: (2012)

Mucosal prime with a replicating vaccinia-based vaccine promotes mucosal immunity against SIV
por: Tang, X, et al.
Publicado: (2012)

The increased sensitivity of CTLs induced by vaccinia vector is developed as intrinsic feature in vivo and independent of microenvironment in vitro
por: Hu, Z, et al.
Publicado: (2012)

OA02-06 LB. Recombinant modified Vaccinia virus ankara expressing HIV-1 genes activates NK subset capable of controlling HIN infection in vitro
por: Cummings, J, et al.
Publicado: (2009)

Protection against highly pathogenic SIV by BCG-SIV recombinant priming and attenuated replicating vaccinia-SIV recombinant boosting
por: Zhang, X, et al.
Publicado: (2012)

P05-14 LB. Analysis of virus swarms to identify vaccine immunogens with improved exposure of epitopes recognized by broadly neutralizing antibodies
por: Berman, P, et al.
Publicado: (2009)

P17-23. Enhanced expression of HIV antigens and improved antigen presentation after infection with replication competent attenuated vaccinia virus in vitro
por: Quakkelaar, E, et al.
Publicado: (2009)

A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination
por: Huang, Xiaoxing, et al.
Publicado: (2009)

Phase I clinical trials of safety and immunogenicity of live cultural influenza vaccine vector-flu
por: Nechaeva, Elena A, et al.
Publicado: (2015)

Enhancing the Immunogenicity of Vaccinia Virus
por: Shchelkunov, Sergei N., et al.
Publicado: (2022)

LB14. Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older
por: Chang, Lee-Jah, et al.
Publicado: (2018)

OA021-01. Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines
por: Jacobs, B, et al.
Publicado: (2009)

The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates
por: Prow, Natalie A., et al.
Publicado: (2020)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

P20-19 LB. Extensive HLA-driven viral diversity following a single-source HIV-1 outbreak in rural China
por: Dong, T, et al.
Publicado: (2009)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

Pre-Clinical Efficacy and Safety of Experimental Vaccines Based on Non-Replicating Vaccinia Vectors against Yellow Fever
por: Schäfer, Birgit, et al.
Publicado: (2011)

P15-29 LB. From ethical principle to practice: Training the trainers
por: Hankins, CA, et al.
Publicado: (2009)

Genes that Control Vaccinia Virus Immunogenicity
por: Shchelkunov, S. N., et al.
Publicado: (2020)

P15-30 LB. An evaluation of prescreen recruitment data: enrolling racial/ethnic minorities in Phase I HIV vaccine clinical trials
por: Johnson, D, et al.
Publicado: (2009)

Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses
por: Riederer, Stephanie, et al.
Publicado: (2021)

P19-52 LB. Assessing and restructuring foreign gene insertion sites for enhanced stability of modified Vaccinia virus ankara recombinants expressing HIV genes
por: Wyatt, L, et al.
Publicado: (2009)

OA07-04 LB. Immunogenicity of ALVAC-HIV® (vCP1521) and AIDSVAX® B/E prime boose vaccination in RV144, the Thai Phase III HIV vaccine trial
por: de Souza, MS, et al.
Publicado: (2009)

Safety and immunogenicity of mammalian cell derived and Modified Vaccinia Ankara vectored African swine fever subunit antigens in swine
por: Lopera-Madrid, Jaime, et al.
Publicado: (2017)

Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein
por: Alexander, J, et al.
Publicado: (2012)

P18-13 LB. Immunogenicity of an autologous dendritic cell anti-HIV therapy in HIV-1 infected individuals
por: Yassine Diab, B, et al.
Publicado: (2009)

Viral vector delivery of Env trimer immunogens
por: Parks, CL, et al.
Publicado: (2012)

Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
por: Koch, Till, et al.
Publicado: (2020)

Attenuation of Replication-Competent Adenovirus Serotype 26 Vaccines by Vectorization
por: Maxfield, Lori F., et al.
Publicado: (2015)

Immunization by Replication-Competent Controlled Herpesvirus Vectors
por: Bloom, David C., et al.
Publicado: (2018)

Virus synthesis and replication: reovirus vs. vaccinia virus.
por: Joklik, W. K.
Publicado: (1980)

OA05-06 LB. First-in-human Phase 1 safety and immunigenicity of an adenovirus serotype 26 HIV-1 vaccine vector
por: Baden, LR, et al.
Publicado: (2009)

Efficacy of the modified vaccinia Ankara virus vaccine and the replication-competent vaccine ACAM2000 in monkeypox prevention
por: Kandeel, Mahmoud, et al.
Publicado: (2023)

Enzymatic processing of replication and recombination intermediates by the vaccinia virus DNA polymerase
por: Hamilton, Michael D., et al.
Publicado: (2005)

Fusion of CTA and CTB gene to immunogen significantly enhances the immunogenicity of DNA vaccine
por: Ren, X, et al.
Publicado: (2012)

P09-19 LB. CTL escape mutations in gag epitopes restricted by protective HLA class I alleles cause substantial reductions in viral replication capacity
por: Boutwell, CL, et al.
Publicado: (2009)

P17-28 LB. The antiviral efficacy of HIV-specific CD8+ T-cells to a conserved epitope is heavily dependent on the infecting HIV-1 isolate
por: Ranasinghe, S, et al.
Publicado: (2009)

Do humans have replication-competent endogenous retroviruses?
por: Belshaw, Robert, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_t0h3q8nuckog1c95peum3827hb